HOME >> BIOLOGY >> NEWS
New monoclonal antibody therapies offer significant survival advantage for breast cancer patients

Paris, France, Monday 31 October 2005 - Results from the first and only interim analysis of an important trial assessing the potential of Herceptin (trastuzumab) to improve disease-free survival (DFS) in HER-2 positive breast cancer patients after adjuvant chemotherapy, have shown that Herceptin affords a significant survival advantage. These new findings were released at the 13th European Cancer Conference (ECCO) on the recommendation of the Independent Data Monitoring Committee.

The study in question, an international, multicentre, randomised, 3-arm trial is being conducted by the Breast International Group (BIG) in collaboration with the pharmaceutical company Roche AG, manufacturers of Herceptin. In total, 5,090 early breast cancer patients have been enrolled into this trial by the 478 participating institutions from Europe, Canada, South Africa, Israel, the Asia Pacific Region, Japan and Latin America. All women accrued had HER-2 positive breast cancer (either node negative or positive) and had completed at least four cycles of an acceptable (neo) adjuvant chemotherapy regimen. For women with hormone receptor positive disease, adjuvant endocrine therapy (most commonly tamoxifen) followed chemotherapy. The average age of study participants is 49 years.

The aim of this trial is to compare the effect of 1 year of Herceptin infusions, given every 3 weeks, with one year of simple observation, on survival primarily DFS but also overall survival (OS), relapse-free survival (RFS) and distant disease free survival (DDFS), as well as comparable assessment of overall and cardiac safety. The study also consists of a 2-year arm where 2 years of 3-weekly Herceptin is being compared with observation.

Results from the 1-year arm of the study, showcased at ECCO 13, show that Herceptin is associated with a significant improvement in DFS in this group of patients. The difference in Herceptin treated women was 85.8% compared to 77.4% of women on observati
'"/>

Contact: Kirsten Mason
kirsten.mason@toniclc.com
44-077-969-55353
Federation of European Cancer Societies
31-Oct-2005


Page: 1 2 3

Related biology news :

1. Report calls for improved monoclonal antibodies against solid tumors
2. First production of human monoclonal antibodies in chicken eggs published in Nature Biotechnology
3. New antibody for EGFR causes lung cancer regression
4. A key antibody, IgG, links cells capture and disposal of germs
5. Research pinpoints West Nile virus antibody binding site
6. A single sugar found responsible for an antibodys ability to treat inflammation
7. Study shows how protein raises antibody output
8. Researchers link specific antibody presence to prevention of mother-to-baby HIV transmission
9. New study shows antibody-interleukin complexes stimulate immune responses
10. High resolution snapshots detail dynamics of a cocaine antibody
11. Immune substances may help antibody-based drugs fight cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/22/2016)... PROVO and SANDY, Utah ... (NSO), which operates the highest sample volume laboratory in ... Tute Genomics and UNIConnect, leaders in clinical sequencing informatics ... the launch of a project to establish the informatics ... NSO has been contracted by the ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/14/2016)... MELBOURNE, Florida , March 14, 2016 ... on the growing mobile commerce market, announces the airing of ... York channels starting the week of March 21 st . ... and CNBC, including its popular Squawk on the Street show. ... company focused on the growing mobile commerce market, announces the ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... ... April 29, 2016 , ... ... used in spinal surgical procedures, today announced the completion of a significant transaction ... for current and future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, John ... Mr. Kelley, a recognized leader and mentor in the Denver area business ...
(Date:4/29/2016)... ... April 29, 2016 , ... Summit for Stem Cell has received a ... a patient-specific stem cell therapy for the treatment of Parkinson’s disease. The Summit research ... at The Scripps Research Institute in San Diego, CA. , The aim ...
Breaking Biology Technology:
Cached News: